UroGen Pharma Ltd. Files 2024 10-K

TL;DR

UroGen Pharma 2024 10-K: $32.5M Revenue, $488K Net Income. Assets $100M, Liabs $42.2M.

AI Summary

UroGen Pharma Ltd. filed its 2024 10-K on March 10, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company's total assets were $100,000,000, with total liabilities amounting to $42,231,746. Revenue for the period was $32,490,119, and net income was $487,787. The filing details their business operations and financial standing.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of UroGen Pharma's financial health and operational performance for the fiscal year 2024, including key figures like revenue and net income.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, UroGen Pharma faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.

Key Numbers

• $100.0B — Total Assets (Represents the company's total resources as of December 31, 2024.)
• $42.2B — Total Liabilities (Indicates the company's total obligations as of December 31, 2024.)
• $32.5B — Revenue (The total income generated from sales for the fiscal year 2024.)
• $0.5B — Net Income (The company's profit after all expenses for the fiscal year 2024.)

Key Players & Entities

• UroGen Pharma Ltd. (company) — Filer of the 10-K report
• 2024-12-31 (date) — Fiscal year end date
• 2025-03-10 (date) — Filing date of the 10-K
• $100,000,000 (dollar_amount) — Total assets reported
• $42,231,746 (dollar_amount) — Total liabilities reported
• $32,490,119 (dollar_amount) — Revenue for the fiscal year
• $487,787 (dollar_amount) — Net income for the fiscal year

FAQ

From the Filing

0001437749-25-006842.txt : 20250310 0001437749-25-006842.hdr.sgml : 20250310 20250310163240 ACCESSION NUMBER: 0001437749-25-006842 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 113 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250310 DATE AS OF CHANGE: 20250310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 25724249 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 10-K 1 urgn20241231_10k.htm FORM 10-K urgn20241231_10k.htm 0001668243 UroGen Pharma Ltd. false --12-31 FY 2024 true true true false true true 0.01 0.01 100,000,000 100,000,000 42,231,746 42,231,746 32,490,119 32,490,119 487,787 577,104 107 89,361 872 119 102,244 102,244 1 320 321 115 797,248 806,222 8,803 3 0 http://www.urogen.com/20241231#RightofuseAssetsOperatingAndFinanceLeases http://www.urogen.com/20241231#RightofuseAssetsOperatingAndFinanceLeases http://www.urogen.com/20241231#RightofuseAssetsOperatingAndFinanceLeases http://www.urogen.com/20241231#RightofuseAssetsOperatingAndFinanceLeases http://www.urogen.com/20241231#LeaseLiabilitiesNoncurrent http://www.urogen.com/20241231#LeaseLiabilitiesNoncurrent http://www.urogen.com/20241231#LeaseLiabilitiesNoncurrent http://www.urogen.com/20241231#LeaseLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent 0 2 100.0 3 2 3 10 0 1 1 3,679,400 3,679,400 false false false false Other expenses primarily consist of insurance, sponsorship, grants, other fees and taxes. $0.2 million and $1.7 million of raw materials are included within other non-current assets on the consolidated balance sheets at December 31, 2024 and December 31, 2023, respectively. These raw materials are not expected to be manufactured and sold within the next 12 months. Changes in non-current inventories are reflected on the consolidated statements of cash flows within the caption of other non-current assets. The loss per share, both basic and diluted, for the first, second, and third quarters of 2024 was revised to record an immaterial correction to the amounts originally reported in the March 31, 2024 Form 10-Q filed on May 13, 2024, June 30, 2024 Form 10-Q filed on August 13, 2024, and September 30, 2024 Form 10-Q filed on November 6, 2024, by incorporating the 3,679,400 shares of pre-funded warrants outstanding as of each respective reporting period, which were not included in the previous calculations and are now reflected in the weighted average shares outstanding. In the course of preparing the 2022 tax returns, adjustments were made for certain nondeductible amounts, reducing net operating loss carryforward and reflected as a change in valuation allowance of approximately $8.9 million in 2023. $6.5 million and $3.0 million of the Amounts paid and payable are included as current portion of the prepaid forward obligation within other current liabilities on the consolidated balance sheets as of December 31, 2024 and December 31, 2023, respectively. 0001668243 2024-01-01 2024-12-31 iso4217:USD 0001668243 2024-06-28 xbrli:shares 0001668243 2025-03-03 thunderdome:item 0001668243 2024-12-31 0001668243 2023-12-31 iso4217:ILS xbrli:shares 0001668243 2023-01-01 2023-12-31 iso4217:USD xbrli:shares 0001668243 us-gaap:CommonStockMember 2022-12-31 0001668243 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001668243 us-gaap:RetainedEarningsAppropriatedMember 2022-12-31 0001668243 us-gaap:AccumulatedOtherComprehensi